Business
GenSpera Engages FLG Partners LLC and Partner Chris Lowe for Strategic Business Advisory Services
GenSpera Engages FLG Partners LLC and Partner Chris Lowe for Strategic Business Advisory Services.
About this update from Rebus Hldgs Inc.
[{"type":"text","content":"\n \n GenSpera, Inc. (OTC/QB: GNSZ), a biotech company developing a novel \n prodrug therapeutic for the treatment of cancer, announces that the \n Company’s board of directors has engaged FLG Partners, LLC and its \n partner Chris Lowe to provide strategic advice to further complement the \n Company’s efforts to strengthen its corporate and clinical development. \n This includes aligning the Company’s long term-goals to optimize the \n clinical and regulatory development of mipsagargin, implement \n cost-efficient processes and advise on business development and funding \n initiatives.\n \n \n “We are delighted to engage the services of this highly regarded \n consultancy, which has a reputation for providing sound strategic and \n operational counsel to companies such as GenSpera. In particular, we \n will be calling upon Chris Lowe’s substantial expertise and proven \n abilities in assisting clinical-stage companies to develop \n well-conceived corporate and financial strategies. The full strategic \n review is designed with a view of enhancing shareholder value,” \n commented the Board of Directors of GenSpera.\n \n \n FLG Partners is a leading CFO consulting and services firm based in \n Silicon Valley and its partners have more than 500 years of collective \n CEO and CFO experience. Mr. Lowe is a partner at the firm and has more \n than 15 years of senior management experience that includes executive \n positions in publicly traded life sciences companies.\n \n \n “It is an exciting time at GenSpera as we evaluate mipsagargin in our \n ongoing Phase 2 trial in patients with glioblastoma and finalize \n preparations to commence a Phase 2 trial in patients with prostate \n cancer,” said Craig Dionne, Ph.D., GenSpera’s CEO. “The complementary \n operational and financial expertise of FLG partners and Chris Lowe will \n help guide us through this critical stage in our corporate development \n and support us in reaching our goal of commercializing an important new \n therapeutic for patients with cancer.”\n \n \n “GenSpera is ripe with opportunity and I look forward to using my \n experience as well as the shared expertise of my colleagues at FLG to \n develop a comprehensive plan that advances GenSpera’s clinical programs \n and puts forth financial ...